Dr. Martens Beheer
Beheer criteriumcontroles 3/4
De CEO Dr. Martens is Ije Nwokorie, benoemd in Jan2025, heeft een ambtstermijn van 1.33 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 303.00K, bestaande uit 49.8% salaris en 50.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde £ 935.95K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 4.2 jaar.
Belangrijke informatie
Ije Nwokorie
Algemeen directeur
UK£303.0k
Totale compensatie
| Percentage CEO-salaris | 49.83% |
| Dienstverband CEO | 1.3yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | 4.5yrs |
| Gemiddelde ambtstermijn bestuur | 4.2yrs |
Recente managementupdates
Recent updates
Narratiefupdate • May 13
DOCS: Future Returns Will Depend On Steady Margins And Long Term Assumptions
Analysts have adjusted their price views on Dr. Martens, reflecting updated assumptions around discount rates, modestly different revenue growth and profit margin expectations, and a slightly altered future P/E multiple. Together, these factors feed into a refreshed £1.41 fair value estimate.Narratiefupdate • Apr 28
DOCS: Future Returns Will Rely On Profit Focus And Stable Long Term Assumptions
Analysts have adjusted their price targets on Dr. Martens upward to £1.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E that are broadly in line with previous estimates but fine tuned to current views. Valuation Changes Fair Value: Modelled fair value remains at £1.41, with no change from the previous estimate.Narratiefupdate • Apr 11
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their price target on Dr. Martens to £1.41 from £1.41. They point to slightly higher assumed discount rates and modestly different revenue growth and profit margin expectations that keep the overall valuation level broadly unchanged.Narratiefupdate • Mar 27
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their fair value assumptions slightly, nudging the implied P/E closer to £19.95 and reflecting small updates to discount rate, revenue growth and profit margin expectations for Dr. Martens. What's in the News Issued earnings guidance for fiscal 2026 with revenue expected to be broadly flat on a constant currency basis as the company focuses on the quality of revenue and profitability (company guidance).Narratiefupdate • Mar 13
DOCS: Future Returns Will Depend On Profit-Led Flat Revenue Guidance In 2026
Analysts have nudged their price target for Dr. Martens higher to £1.41, citing modest adjustments to assumptions about the discount rate, revenue, profit margin and future P/E in their updated models. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Narratiefupdate • Feb 27
DOCS: Future Returns Will Depend On Prioritising Profitability Over Near Term Revenue Expansion
Analysts have lifted their price target for Dr. Martens to £1.41, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin and future P/E that collectively point to a modestly improved risk and earnings profile. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Analyseartikel • Feb 12
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0085
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0085 per share on the 9th of April. This...Narratiefupdate • Feb 10
DOCS: Future Returns Will Depend On Expanding Reclaimed Leather Sustainability Collaboration
Analysts have adjusted their price targets for Dr. Martens modestly, reflecting revised assumptions around the discount rate, expected revenue growth, profit margins and a higher future P/E multiple, which together temper the valuation outlook while still supporting a measured premium on earnings. What's in the News Dr. Martens and materials company Gen Phoenix are marking four consecutive seasons of collaboration, extending their work with reclaimed leather under the Genix Nappa line.Narratiefupdate • Jan 26
DOCS: Future Returns Will Rely On Reclaimed Leather Sustainability Partnership
Analysts have adjusted their price targets for Dr. Martens, reflecting updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple. Taken together, these factors point to a revised view of the shares' potential value, even though the fair value estimate remains at £1.41.
Narratiefupdate • Jan 11
DOCS: Future Returns Will Rely On Margins And Long Term Sustainability Partnership
Analysts have made a modest trim to their price target on Dr. Martens, reflecting slightly adjusted assumptions around discount rates, revenue growth, profit margins and future P/E, while still seeing the shares as aligned with an updated fair value of 0.8x. What's in the News Dr. Martens and Gen Phoenix mark four consecutive seasons of working together on reclaimed leather products under the Genix Nappa line, highlighting a multi year partnership rather than a short pilot or capsule approach (Key Developments).Narratiefupdate • Dec 26
DOCS: Future Returns Will Depend On Margin Execution And Sustainability Delivery
Analysts have modestly adjusted their price target on Dr. Martens to 75 GBp, reflecting slightly higher long term revenue growth and profit margin assumptions while maintaining a broadly Neutral stance. Analyst Commentary Analyst commentary around Dr. Martens has remained measured, with the latest work reiterating a Neutral stance and a 75 GBp price target, signaling limited upside in the near term.Narratiefupdate • Dec 12
DOCS: Modest Upside Outlook Will Hinge On Margin Recovery And Sustainability Expansion
The analyst price target for Dr. Martens has been modestly raised to £0.80 from £0.75, as analysts factor in slightly stronger expectations for revenue growth, profit margins, and future earnings multiples, while still maintaining a cautious overall stance. Analyst Commentary Recent Street research has reinforced a measured stance on Dr. Martens, with coverage reinstated at a neutral rating and a price target that sits below longer term historical trading levels.Analyseartikel • Dec 01
Shareholders Should Be Pleased With Dr. Martens plc's (LON:DOCS) Price
Dr. Martens plc's ( LON:DOCS ) price-to-earnings (or "P/E") ratio of 48.9x might make it look like a strong sell right...Analyseartikel • Nov 04
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 26% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.13 based on 2 Stage Free Cash Flow to Equity Dr. Martens...
Narratiefupdate • Oct 08
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Analysts have raised their price target on Dr. Martens from £0.80 to £1.12 per share, citing expectations that 2025 will mark a turning point for the company and stating that market valuations do not yet reflect its long-term growth potential. Analyst Commentary Market watchers have offered mixed insights following the recent upgrade and price target increase for Dr. Martens.Analyseartikel • Aug 26
Returns On Capital Signal Tricky Times Ahead For Dr. Martens (LON:DOCS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Narratiefupdate • Aug 19
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Despite a notable downgrade in forecast revenue growth and a higher projected future P/E, analysts have nonetheless raised Dr. Martens’ consensus price target from £0.898 to £0.952. What's in the News The Board of Dr. Martens proposed a final dividend of 1.70 pence, maintaining the total dividend for fiscal year 2025 at 2.55 pence, equal to the prior year, pending shareholder approval.Analyseartikel • Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Dr. Martens fair value estimate is UK£1.09 Dr. Martens...Analyseartikel • Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017
Dr. Martens plc's ( LON:DOCS ) dividend will be increasing from last year's payment of the same period to £0.017 on 8th...Analyseartikel • Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings
Dr. Martens plc's ( LON:DOCS ) stock was strong despite it releasing a soft earnings report last week. Our analysis...Analyseartikel • Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nieuw narratief • Mar 14
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.Analyseartikel • Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dr. Martens plc ( LON:DOCS ) shareholders would be excited to see that the share price has had a great month, posting a...Analyseartikel • Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
The investors in Dr. Martens plc 's ( LON:DOCS ) will be rubbing their hands together with glee today, after the share...Analyseartikel • Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
The Dr. Martens plc ( LON:DOCS ) share price has fared very poorly over the last month, falling by a substantial 30...Analyseartikel • Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Key Insights Dr. Martens' estimated fair value is UK£1.31 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Analyseartikel • Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
The market was pleased with the recent earnings report from Dr. Martens plc ( LON:DOCS ), despite the profit numbers...Analyseartikel • May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Dr. Martens plc ( LON:DOCS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Analyseartikel • Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Analyseartikel • Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.32 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Analyseartikel • Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
With a price-to-earnings (or "P/E") ratio of 6.9x Dr. Martens plc ( LON:DOCS ) may be sending very bullish signals at...Analyseartikel • Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0156 per share on the 2nd of February...Analyseartikel • Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dr. Martens plc's ( LON:DOCS ) investors are due to receive a payment of £0.0156 per share on 2nd of February. This...Analyseartikel • Oct 12
Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analyseartikel • Sep 13
Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Key Insights Dr. Martens' estimated fair value is UK£1.88 based on 2 Stage Free Cash Flow to Equity Current share price...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | UK£24m |
| Dec 29 2025 | n/a | n/a | UK£20m |
| Sep 28 2025 | n/a | n/a | UK£15m |
| Jun 28 2025 | n/a | n/a | UK£10m |
| Mar 30 2025 | n/a | n/a | UK£5m |
| Dec 30 2024 | n/a | n/a | UK£17m |
| Sep 29 2024 | n/a | n/a | UK£29m |
| Jun 29 2024 | n/a | n/a | UK£49m |
| Mar 31 2024 | UK£57k | n/a | UK£69m |
| Dec 31 2023 | n/a | n/a | UK£86m |
| Sep 30 2023 | n/a | n/a | UK£103m |
| Jun 30 2023 | n/a | n/a | UK£116m |
| Mar 31 2023 | UK£67k | n/a | UK£129m |
| Dec 31 2022 | n/a | n/a | UK£153m |
| Sep 30 2022 | n/a | n/a | UK£177m |
| Jun 30 2022 | n/a | n/a | UK£179m |
| Mar 31 2022 | UK£65k | n/a | UK£181m |
| Dec 31 2021 | n/a | n/a | UK£118m |
| Sep 30 2021 | n/a | n/a | UK£54m |
| Jun 30 2021 | n/a | n/a | UK£44m |
| Mar 31 2021 | UK£11k | n/a | UK£35m |
Compensatie versus markt: De totale vergoeding ($USD 407.12K ) Ije } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 1.58M ).
Compensatie versus inkomsten: De vergoeding van Ije is het afgelopen jaar met meer dan 20% gestegen.
CEO
Ije Nwokorie (55 yo)
1.3yrs
Tenure
UK£303,000
Compensatie
Mr. Onyeije Ogueri Nwokorie, also known as Ije, is CEO & Director at Dr. Martens Limited since January 06, 2025. He was Chief Brand Officer at Dr. Martens plc since February 01, 2024. He is Independent Non...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 1.3yrs | UK£303.00k | 0.14% £ 936.0k | |
| CFO & Director | 2yrs | UK£1.78m | 0.027% £ 177.3k | |
| Chief Operating Officer | 7.9yrs | geen gegevens | geen gegevens | |
| Chief Technology Officer | no data | geen gegevens | geen gegevens | |
| Director of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
| Chief People Officer | no data | geen gegevens | geen gegevens | |
| Chief Digital Officer | 8.1yrs | geen gegevens | geen gegevens | |
| President of APAC | 6.7yrs | geen gegevens | geen gegevens | |
| Chief Product Officer | 4.4yrs | geen gegevens | geen gegevens | |
| President of Americas | 4.5yrs | geen gegevens | geen gegevens | |
| President of EMEA | 3yrs | geen gegevens | geen gegevens | |
| Director of Sustainability | no data | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DOCS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Executive Director | 1.3yrs | UK£303.00k | 0.14% £ 936.0k | |
| CFO & Director | 2yrs | UK£1.78m | 0.027% £ 177.3k | |
| Independent Non-Executive Director | 1.2yrs | UK£1.00k | 0.021% £ 135.6k | |
| Independent Non-Executive Director | 3yrs | UK£68.00k | 0.0079% £ 51.9k | |
| Non-Independent Non-Executive Director | 1.2yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 5.3yrs | UK£68.00k | 0.0021% £ 13.7k | |
| Independent Non-Executive Director | 5.3yrs | UK£96.00k | 0.010% £ 67.3k | |
| Representative Non-Independent Non-Executive Director | 5.3yrs | geen gegevens | geen gegevens | |
| Senior Independent Non-Executive Director | 5.3yrs | UK£101.00k | 0.0048% £ 31.2k | |
| Chair of the Board | 10.7yrs | UK£342.00k | 0.81% £ 5.3m |
4.2yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DOCS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/21 02:17 |
| Aandelenkoers aan het einde van de dag | 2026/05/21 00:00 |
| Inkomsten | 2026/03/29 |
| Jaarlijkse inkomsten | 2026/03/29 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Dr. Martens plc wordt gevolgd door 13 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Richard Taylor | Barclays |
| Anne Critchlow | Berenberg |
| David Roux | BofA Global Research |